Recent IPO Insys Therapeutics soars after posting a solid Q2

|About: Insys Therapeutics, Inc. (INSY)|By:, SA News Editor

Recent IPO Insys Therapeutics (INSY +23%) posts its first earnings report since its debut, easily topping Q2 estimates as revenue nearly doubled from the previous quarter.

Subsys generated $18.5M in net revenue, up 90.8% Q/Q from $9.7M in Q1.

Gross margin was 86%, compared to 34% for Q212, primarily a result of a big jump in sales of Subsys which has a higher gross margin than Dronabinol.